H.I.G. Capital acquires Canadian biopharma company

The $34 billion private equity powerhouse H.I.G. Capital announced the acquisition of BioVectra in a bid to further expand the Canadian company’s biopharmaceutical business.

Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.